<DOC>
	<DOCNO>NCT02878499</DOCNO>
	<brief_summary>The primary objective study undertake longitudinal investigation impact sleep circadian rhythm disturbance cognitive behavioural trajectory child autism spectrum disorder ( ASD ) age 3-10 year old . This innovative study use objective quantifiable measure sleep circadian rhythm addition subjective measure . The investigator aim assess hypothesis , pre-pubertal child ASD , 1. sleep disturbance correlate circadian rhythm disturbance ; 2. sleep circadian rhythm disturbance negatively correlate cognitive performance positively correlate behavioural disturbance ; 3. sleep circadian rhythm disturbance , notably abnormal melatonin secretion , impact cognitive behavioural development child ASD , depend age ( prospective longitudinal analysis ) .</brief_summary>
	<brief_title>Do Sleep Circadian Rhythm Disturbances Impact Cognitive Behavioural Development Children With Autism ?</brief_title>
	<detailed_description />
	<mesh_term>Autistic Disorder</mesh_term>
	<mesh_term>Autism Spectrum Disorder</mesh_term>
	<mesh_term>Child Development Disorders , Pervasive</mesh_term>
	<criteria>Inclusion criterion : Age : 3 8 year age inclusion , per define entry age ( longitudinal accelerate design ) Diagnostic criterion autism spectrum disorder ( ASD ) Autism Diagnostic Interview ( ADI ) revise ( R ) score compatible ASD diagnosis Autism Diagnostic Observation Schedule ( ADOS ) score compatible ASD diagnosis Study information understood Study consent sign parent legal representative child child capable express consent Stable medication 2 monthsperiod precede inclusion evaluation period ( exception : ( 1 ) medication mention exclusion criterion , ( 2 ) new medication instaurated two evaluation period exclusion criterion , take account data analysis ) Compliance study procedure Priori clinical medical examination Child affiliate social security Concerning sleep disorder : discovery primary sleep disorder ( e.g . : sleep apnea syndrome , restless legs syndrome , periodic limb movement sleep ) well treatment criterion terminate study take account data analysis Exclusion criterion : Secondary autism : e.g . associate Rett syndrome , fragile X syndrome , Down syndrome , Bourneville tuberous sclerosis , von Recklinghausen disorder , Cytomegalovirus ( CMV ) encephalitis , congenital rubeola , phenylketonuria . Current treatment melatonin melatonin agonist study entry ( baseline assessment ) Changes medication 2 monthsperiod precede study ( exception : new medication instaurated two evaluation period exclusion criterion , take account data analysis ) Transmeridian travel ( &gt; 2 time zone ) month precede study Participation research study 3 month period precede study Treatment betablockers , local systemic nonsteroidal antiinflammatory ( NSAI ) agent , benzodiazepine , antidepressant Severe intercurrent disorder . Severe allergy .</criteria>
	<gender>All</gender>
	<minimum_age>3 Years</minimum_age>
	<maximum_age>8 Years</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>autism</keyword>
	<keyword>autism spectrum disorder</keyword>
	<keyword>ASD</keyword>
	<keyword>sleep</keyword>
	<keyword>Circadian</keyword>
	<keyword>Biological rhythm</keyword>
	<keyword>melatonin</keyword>
	<keyword>Cognition</keyword>
	<keyword>Behavior</keyword>
	<keyword>Longitudinal</keyword>
	<keyword>Longitudinal accelerate design</keyword>
</DOC>